Men can develop breast cancer. Its rarity does not make a lump, nipple retraction or bloody discharge unimportant. At the same time, not every enlarged male breast is cancer; there are benign explanations too. The first task is to establish what the particular change represents. Once cancer is confirmed, the consultation should focus on the findings that actually determine treatment.
The NCI information on male breast cancer describes clinical examination, mammography or ultrasound, and biopsy among the diagnostic methods. Tissue examination establishes the disease type. A request saying only “breast tumour” does not tell a receiving clinician whether this means proven cancer, a suspicious scan or a benign condition.
Provide the complete pathology report, including the sample site and collection date. For another opinion, the hospital may request the material itself for review. A message saying the change is hormonal cannot replace a diagnosis, and a photograph of the breast cannot establish one.
Planning includes tests for oestrogen and progesterone receptors, HER2 and other relevant tumour features. Male breast cancer is commonly hormone receptor-positive, but that finding still needs to be established in the actual tumour. Subtype and stage help determine the roles of surgery, radiation and systemic treatment.
Endocrine treatment may be an important component of care. Its regimen should not simply be copied from a female relative with a similar diagnosis: sex, health, treatment purpose and the particular medicine matter. Tell the team about all medicines, including hormonal products and supplements. Supply the full list for assessment rather than stopping them independently before the consultation.
Men usually have less breast tissue, which can make adequate tumour removal with conservation more difficult. Mastectomy is therefore common, although some cases allow a breast-conserving approach. The decision depends on the location and size of the tumour in relation to the breast and other factors, not a rule that all men must have the same operation.
Underarm node assessment and the need for radiotherapy require their own explanation. Establish what the operation includes, where scars will lie, possible changes in sensation and the expected recovery restrictions. Questions about appearance and physical work deserve attention alongside the procedure’s name.
Male breast cancer is a reason to discuss genetic counselling. Inherited changes, including BRCA variants, can have implications for cancer treatment and blood relatives. Family history should include both the mother’s and father’s sides. Where information is available, the cancer type and approximate age at diagnosis are useful.
This does not mean relatives will inevitably develop cancer or immediately need identical testing. The NCI BRCA guide distinguishes a pathogenic inherited variant from a negative finding or a variant of uncertain significance. Genetic counselling connects the actual result to appropriate decisions. An unknown or apparently unremarkable family history does not make male breast cancer impossible.
Send pathology, receptor findings, imaging, the medicine list and records of any treatment already given. Identify the immediate question: diagnosis confirmation, surgical extent or the systemic-treatment phase. If surgery has already taken place, include the final pathology and operation note, with the lymph node information.
When arranging an oncology assessment in Turkey, establish which team will review male breast cancer and how you will receive a written plan in a language you understand. A rare diagnosis calls for relevant expertise and a clear follow-up pathway, not a promise of a universal special technique.
New suspicious breast changes should be assessed promptly where you are rather than held back until an overseas trip. The documents from that initial assessment can then make a second opinion more useful and reduce avoidable repetition.
Medicina Turkey patient information. General guidance; individual medical decisions should be discussed with the treating clinician.